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Introduction	
Denmark	 and	 the	 United	 Kingdom	 (UK)	 	 are	 welfare	 states,	 which	 have	 often	 been	 described	
respectively	 as	 “social	 democratic”	 (Scandinavia)	 and	 “liberal”	 (Anglo-Saxon	 countries)	 (Esping-
Andersen	1990).	Historically,	the	two	countries	have	often	chosen	quite	dissimilar	pathways	with	
regard	 to	 societal	 challenges	 such	 as	 poverty,	 health	 care,	 unemployment,	 education	 and	 child	
care.	 However,	 both	 countries	 are	 amongst	 those	 few	 European	 countries	 that	 have	 a	 long	
tradition	and	an	elaborate	system	for	providing	opioid	substitution	treatment	(OST)	(for	example	
methadone)	to	heroin	users	(Dahl	2005;	Duke,	Herring	et	al.	2013;	Frank,	Bjerge	et	al.	2013;	Thom,	
Duke	et	al.	2013).	 In	Denmark,	OST	has	been	offered	to	drug	users	since	the	1960´s.	 	 In	the	UK,	
medical	 doctors	 could	 prescribe	 addictive	 drugs	 (including	 heroin	 and	 injectable	 opioid	
substitutes)	 as	 part	 of	 treatment	 since	 1926,	 but	 there	 was	 a	 shift	 towards	 prescribing	 oral	
methadone	 by	 the	 1970s.	 In	 both	 countries,	 the	 increasing	 use	 of	 substitution	 treatment	 was	
implemented	as	a	response	to	a	growing	population	of	young,	 recreational	heroin	users.	Due	to	
the	 fact	 that	 opioid	 substitution	medications	 are	 prescription	 drugs,	medical	 professionals	 have	
always	played	key	roles	in	treatment,	although	to	varying	degrees	(Dahl	2005;	Frank,	Bjerge	et	al.	
2013;	 Thom,	 Duke	 et	 al.	 2013;	 Berridge,	 2013;	 Bjerge,	 Houborg	 et	 al.	 2015).	 In	 this	 article,	 we	
examine	how	different	treatment	policies	and	treatment	philosophies	have	increased	the	position	
of	 medical	 professionals	 as	 stakeholders	 in	 substitution	 treatment	 policies	 and	 practices.	 We	
define	a	stakeholder	as	any	actor	who	can	affect	and/or	be	affected	by	the	activities	(e.g.	policies,	
practices,	 interventions)	 in	 question	 (Freeman	 1984,	 Orts	 &	 Strudler	 2002).	 	 In	 our	 case	 study,	
these	 actors	 or	 stakeholders	 include	medical	 professionals,	 such	 as	 general	 practitioners	 (GPs),	
psychiatrists,	doctors	working	 in	substitution	treatment	centres,	nurses	or	social	and	health	care	
assistants,	who	are	engaged	in	policy	in	relation	to	substitution	treatment	or	the	practices	of	this	
work.	
The	 idea	 to	 explore	 the	 different	 spaces	 medical	 professionals	 occupy	 as	
stakeholders	in	policy	and	practice	emerged	from	an	ongoing	study	with	researchers	from	Austria,	
Denmark,	Finland,	Italy,	Poland	and	the	UK	focusing	on	various	stakeholders´	roles	and	influence	in	
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the	addiction	fields.1	The	project	formed	a	part	of	the	EU-funded	project:	Addictions	and	Lifestyles	
in	Contemporary	Europe:	Reframing	Addictions	Project	(ALICE	RAP).2	When	analysing	the	materials	
for	the	overall	project,	it	became	clear	to	us	that	the	role	of	medical	professionals	had	developed	
quite	differently	in	Denmark	and	the	UK,	despite	the	similarities	with	regard	to	the	increasing	use	
of	OST	programmes	as	a	response	to	new	heroin	users	in	both	countries	in	the	1960s/1970s.	The	
UK	has	a	long	history	of	dominance	of	medical	professionals	(both	generalists	(GPs)	and	specialists	
(psychiatrists))	 in	 drugs	 treatment	 (Mold,	 2008;	 Berridge,	 2013;	 Duke,	 Herring	 et	 al,	 2013).	 In	
Denmark,	 the	medical	 perspective	 has	 evolved	 over	 time,	 and	 for	many	 years	 a	 social	 problem	
approach	dominated	the	 field	 (Frank,	Bjerge	et	al.	2013;	Bjerge,	Houborg	et	al;	2015).	However,	
within	 the	 past	 fifteen	 years,	 a	 shift	 can	 be	 identified	 in	 both	 countries.	 In	 Denmark,	 a	 trend	
towards	 medicalisation	 can	 be	 traced	 in	 substitution	 treatment.	 This	 is	 in	 contrast	 to	 the	 UK,	
where	a	recent	trend	towards	de-medicalisation	can	be	traced.	As	 in	all	kinds	of	policy	changes,	
multiple	 factors	 are	 at	 play	 when	 shifts	 occur	 (Kingdon	 1995),	 including	 changing	 political,	
economic	and	social	contexts,	new	technology,	changing	user	groups,	the	rise	of	new	problems	–	
and	not	least	the	changing	roles	of	prominent	stakeholders	in	a	given	field.	On	the	one	hand,	the	
rise	of	 the	medical	voice	 in	the	Danish	substitution	treatment	field	was	promoted	by	a	group	of	
entrepreneurial	medical	 stakeholders	 as	well	 as	 changes	 in	 the	 organisation	 of	 drug	 treatment,	
broader	societal	focus	on	health	and	medication,	and	changes	in	the	drug	user	population.	On	the	
other	hand,	the	British	medical	voice	has	recently	been	challenged	by	a	“recovery”	movement	led	
by	a	number	of	advocacy	organisations,	recovery	advocates	from	the	United	States,	the	residential	
rehabilitation	 sector,	 some	 researchers	 and	media	 stakeholders.	 Both	 countries´	 developments	
relate	 to	 broader	 societal	 developments,	 and	we	 investigate	 how	 such	 divergent	 developments	
emerge	and	how	medical	professionals	as	stakeholders	enhanced	their	role	as	experts	in	the	field,	
through	a	variety	of	tactics,	including	the	use	and	production	of	“evidence”,	which	became	a	key	
tool	to	promote	specific	stakeholder´s	perspectives	in	these	processes.			
When	 analysing	 debates	 in	 substitution	 treatment	 practices	 and	 wider	 issues	
surrounding	 the	 development	 of	 drug	 policy,	 key	 questions	 include	 ‘what	 counts	 as	 expertise’,	
‘what	counts	as	evidence’	and	‘who	decides	what	counts’?	(cf.	Duke	&	Thom,	2014).	This	refers	to	
the	continuing	struggle	over	which	groups	“own”	the	right	to	define	and	act	on	the	 issue.	There	
are	 often	 conflicts	 between	 those	 stakeholders	 who	 define	 drug	 use	 as	 a	medical	 problem	 for	
																																								 																				
1	For	further	descriptions	of	results	of	this	project,	see	Beccaria	&	Rolando,	2013;	Frank	et	al,	2013;	Duke	et	al,	2013;	
Moskalewicz	and	Welbel,	2013;	Eisenbach-Stangl,	2013;	Beccaria	&	Rolando,	2014;	Thom	et	al,	forthcoming;	Houborg	
&	Frank	2014;	Houborg,	Frank	&	Bjerge	2014;	and	Bjerge,	Duke	et	al.	2015.	
2	 The	 research	 leading	 to	 these	 results	 or	 outcomes	 has	 received	 funding	 from	 the	 European	 Union's	 Seventh	
Framework	 Programme	 (FP7/2007-2013),	 under	 Grant	 Agreement	 nº	 266813	 -	 Addictions	 and	 Lifestyle	 in	
Contemporary	 Europe	 –	 Reframing	 Addictions	 Project	 (ALICE	 RAP	 –	 www.alicerap.eu).Participant	 organisations	 in	
ALICE	RAP	can	be	seen	at	http://www.alicerap.eu/about-alice-rap/partner-institutions.html.The	views	expressed	here	
reflect	 those	 of	 the	 authors	 only	 and	 the	 European	 Union	 is	 not	 liable	 for	 any	 use	 that	 may	 be	 made	 of	 the	
information	contained	therein.	
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which	medical	 intervention	 is	needed	and	 those	who	define	drug	use	more	as	a	 social	problem	
which	 require	 interventions	 from	 a	wider	 range	 of	 services,	 professionals	 and	 non-professional	
groups.	There	can	also	be	challenges	to	the	dominance	of	professional	definitions	and	ownership	
of	 the	drug	 issue	by	 consumers	 or	 the	 ‘objects’	 of	 these	definitions,	 policies	 and	practices.	 The	
increasing	emphasis	on	service	user	 involvement	and	 incorporating	user	groups	and	experiential	
knowledge	 into	 the	 development	 of	 treatment	 provision	 and	 in	 wider	 policy	 development	
initiatives	can	be	identified	as	key	trends	in	both	countries	(see	Bjerge,	Duke,	Frank	et	al,	2015).3	
In	 order	 to	 compare	 and	 contrast	 the	 role	 of	 medical	 stakeholders	 in	 the	
development	 of	 substitution	 treatment	 policy	 and	 practice	 in	 Denmark	 and	 UK,	 we	 begin	 by	
outlining	the	research	design	and	methodology	employed	in	the	study;	we	then	briefly	summarize	
the	key	historical	shifts	in	relation	to	their	role	in	drugs	policy	and	practice	in	both	countries;	we	
then	 draw	 on	 our	 case	 studies	 to	 examine	 the	 current	 activities	 and	 influence	 of	 stakeholders	
(with	a	focus	on	medical	professionals);	and	finally	we	explore	the	key	similarities	and	differences	
in	terms	of	the	medical	profession’s	involvement	in	drug	policy	and	practice	and	the	factors	which	
have	impacted	on	their	roles	in	both	countries.			
	
Research	Design	and	Methodology	
The	article	is	based	on	previous	research	literature	on	opioid	substitution	treatment	and	policy	in	
Denmark	 and	 UK4,	 on	 documentary	 analyses	 (mainly	 key	 policy	 and	 treatment-related	
documents),	as	well	as	qualitative,	in-depth	interviews	with	various	stakeholders	and	stakeholder	
groups,	including	medical	professionals,	in	both	countries.	In	Denmark,	seventeen	key	informants	
were	 interviewed	 (including	 civil	 servants,	 treatment	 providers,	 researchers,	 non-governmental	
organisations	 (NGOs),	 and	 professional	 organisations	 in	 the	 field).	 In	 the	 UK,	 twenty	 key	
informants	were	interviewed	(including	policy	makers,	researchers/scientists,	and	representatives	
from	 advocacy	 organisations,	 the	 treatment	 sector,	 pharmaceutical	 industry	 and	 social	
enterprises).	 In	 both	 countries,	all	 of	 the	 interviewees	 were	 asked	 to	 reflect	 on	 the	 role	 and	
influence	of	different	stakeholders	and	stakeholder	groups,	including	medical	professionals,	in	the	
development	of	policy	and	practice.5			
	
																																								 																				
3	This	article	focuses	on	the	comparative	aspect	of	the	shifting	role	of	medical	stakeholders	in	OST.	For	more	in-depth	
information	of	the	history	of	OST	in	Denmark	and	the	UK	see	Frank,	Bjerge	&	Houborg	(2013)	and	Duke,	Herring,	
Thickett	and	Thom	(2013).	
4	The	UK	devolved	administrations	(Northern	Ireland,	Scotland,	and	Wales)	have	their	own	strategies	around	drugs	
and	alcohol	in	areas	where	responsibility	is	devolved.	Some	of	the	policy	areas	covered	by	the	Drug	Strategy	2010	(HM	
Government,	2010)	including	health,	housing,	education	and	social	care	therefore	only	cover	England.	
5	For	more	in-depth	descriptions	of	data	used	in	Denmark,	see	Frank,	Bjerge	&	Houborg	(2013)	and	in	the	UK,	see	
Duke,	Herring,	Thickett	&	Thom	(2013).		
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A	brief	historical	account	of	medical	stakeholders	in	Danish	and	British	drugs	policy	and	practice.		
Denmark	
Medical	 stakeholders	 have	 played	 a	 role	 in	 treatment	 for	 drug	 addiction	 in	 Denmark	 since	 the	
1940s	when	treatment	was	placed	within	the	psychiatric	system	(Dahl	2005).	Up	until	the	1960s	
drug	 addiction	 was,	 however,	 a	 very	 rare	 condition	 (Ringgaard	 2010).	 Only	 in	 the	 1960s	 when	
morphine	 and	 heroin	 started	 to	 be	 used	 as	 an	 intoxicant	 among	 young	 people,	 and	 became	
symbols	 of	 particular	 youth	 groups	 and	 subcultures,	 substitution	 treatment	 inspired	 by	 clinical	
trials	in	the	US	using	methadone	supplemented	with	psychosocial	treatment	(Dole,	Nyswander	&	
Kreek	 1966)	 started	 to	 emerge	 in	 Denmark	 and	 began	 to	 be	 prescribed	 to	 drug	 users	 by	 GPs.	
When	 drug	 addiction	 became	 a	 growing	 problem	 in	 the	 1970s,	 new	 policy	 initiatives	 were	
developed	and	implemented.	Drug	treatment	was	framed	as	a	social	problem	and	moved	from	a	
topic	 that	 primarily	 should	 be	 dealt	 with	 by	 the	 national	 health	 services	 to	 the	 social	 welfare	
system	 (Houborg,	 2006;	 Winsløw,	 1984).	 In	 the	 1970s,	 drug	 treatment	 was	 placed	 under	 the	
control	 of	 the	 municipalities.	 It	 was	 only	 abstinent-based	 treatment	 models	 and	 it	 was	 kept	
primarily	within	the	social	care	services.	GPs	were,	however,	still	able	to	prescribe	methadone	as	a	
treatment	for	drug	addiction	(Houborg,	2006;	Winsløw	&	Ege,	1983).	Different	stakeholders	were	
involved	in	drug	treatment,	especially	social	workers	and	social-pedagogical	counsellors,	whereas	
medical	professionals	were	 fewer	 in	numbers,	 less	visible,	and	 less	vocal	as	 stakeholders	during	
this	 period.	 Substitution	 treatment	 policy	 was	 defined	 locally	 by	 GPs	 and	 depended	 on	 their	
willingness	 to	 prescribe	 methadone,	 in	 an	 era	 where	 the	 dominant	 policy	 definition	 of	 drug	
addiction	was	that	it	was	a	social,	rather	than	a	medical	problem	(Houborg,	2006).	In	effect,	a	two-
tier	treatment	system	was	developed	in	which	little	or	no	co-operation	existed	between	the	two	
sectors	–	municipal	drug	free	treatment	initiatives	and	GPs	prescribing	of	methadone.	The	two	tier	
system	was	also	represented	structurally	in	that	treatment	for	drug	addiction	was	placed	both	in	
the	Ministry	of	Health	and	the	Ministry	of	Social	Affairs.		
Drug	 policy	 in	 Denmark	 is,	 however,	 apparent	 not	 only	 welfare	 initiatives	 such	 as	 drug	
treatment,	but	also	defined	by	the	control	system.	Parallel	to	treatment	initiatives,	the	control	of	
drugs	 has	 been	 part	 of	 the	 political	 landscape	 since	 1955,	 when	 the	 first	 drug	 law	 was	
implemented	 in	 Denmark	 (Laursen	&	 Jepsen,	 2002).	 However,	 spanning	 35	 years	 from	 1969	 to	
2004,	Denmark	also	has	had	a	more	 liberal	policy	on	drugs	characterized	by	decriminalisation	of	
possession	 for	own	use	of	cannabis	and	a	 legal	differentiation	between	users	and	dealers	 (ibid).	
The	balance	between	these	two	perspectives	on	drug	policy	-	welfare	and	control	–	has	changed	
over	 the	 years	 (Houborg,	 2010),	 especially	 from	 the	mid-1980s	when	harm	 reduction	 ideas	 and	
initiatives	began	to	gain	importance	in	Denmark,	among	other	things	due	to	HIV/AIDS	and	later	on	
Hepatitis	epidemics.	The	liberal	drug	policy	in	Denmark	has	not	only	been	defined	as	such	because	
of	the	decriminalisation	of	personal	use	of	cannabis,	but	also	because	of	the	early	development	of	
harm	reduction	initiatives	and	hence	a	more	intense	focus	on	health	and	the	health-related	harms	
of	drug	addiction.	Since	the	mid-1990s,	harm	reduction	initiatives	such	as	needle	exchange,	street	
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level	nursing,	 low	threshold	methadone	treatment	and	drop-in	centres	have	gradually	expanded	
and	 become	 part	 of	 services	 offered	 to	 drug	 users,	 followed	 by	 the	 recent	 implementation	 of	
heroin-assisted	 treatment	 and	 drug	 consumption	 rooms	 in	 2012.	 The	 balance	 between	welfare	
and	control	also	changed	with	the	2004	changes	in	drug	laws.	While	there	was	a	particular	shift	in	
drug	laws	in	2004	as	outlined	above,	the	length	of	possible	sentences	has	increased	regularly	since	
1955	(Laursen	&	Jepsen,	2002)	to	today’s	level	of	sentencing	for	possession,	dealing	and	smuggling	
of	drugs	(for	details	see	Frank,	2008,	Houborg,	2010).		
The	involvement	of	medical	professionals	and	the	conceptualization	of	drug	addiction	as	a	
medical	problem	became	more	and	more	prominent	in	the	1990s	with	organisational	changes	to	
the	public	drug	treatment	system	in	1996.	Here	the	government	made	all	drug	treatment	a	public	
monopoly	with	 county-based	drug	 treatment	 centres	 the	only	entry	point	 for	drug	users	 to	any	
kind	of	drug	treatment,	 including	OST.	The	prescribing	of	methadone	was	no	 longer	possible	for	
GPs	(unless	it	was	delegated	from	a	county	treatment	centre),	and	methadone	prescribing	was	to	
become	more	common	with	 the	 implementation	of	 the	Circular	on	 the	Prescription	of	Addictive	
Drugs	by	the	National	Board	of	Health	(Sundhedsstyrelsen,	1995).	The	previous	locally	determined	
policy	 on	methadone	 prescribing	 by	 GPs	was	 now	moved	 to	 doctors	 employed	 by	 county	 drug	
treatment	 centres	 who	 would	 now	 follow	 national	 guidelines	 on	 methadone	 prescribing.	 The	
Circular	on	the	Prescription	of	Addictive	Drugs	was	updated	in	2008	(Sundhedsstyrelsen,	2008)	and	
made	 more	 detailed	 on	 how	 to	 implement	 substitution	 treatment	 compared	 to	 the	 previous	
circular	 from	1996.	Whereas	 the	old	 circular	was	only	advisory,	 the	new	one	became	statutory.	
Prescribing	 methadone	 or	 other	 substitution	 drugs	 has	 thus	 been	 regulated	 by	 circulars	 and	
guidelines.	After	the	update	of	the	prescription	guidelines,	the	Board	of	Social	Services	launched	a	
new	set	of	guidelines	for	the	psycho-social	part	of	treatment	(Servicestyrelsen,	2010).	The	changes	
in	1996	also	meant	that	medical	stakeholders	involved	in	substitution	treatment	were	now	moved	
to	 the	 county-based	 treatment	 centres	 and	 should	work	along	with	other	 kinds	of	 stakeholders	
(e.g.	 counsellors,	 psychologists,	 or	 social	 workers),	 at	 least	 in	 relation	 to	 outpatient	 and	 day	
treatment.	Residential	 treatment	was	 still	 placed	 in	other	 institutions,	but	drug	users	had	 to	be	
referred	to	residential	treatment	through	the	county-based	treatment	centres.	A	broad	spectrum	
of	stakeholders	was	thus	involved	in	shaping	substitution	treatment	policy	and	practice,	including	
social	workers,	bureaucrats,	researchers,	psychologists,	medical	doctors,	nurses,	psychiatrists,	and	
social	 and	 health	 care	 assistants.	 The	 organisational	 changes	 also	 made	 different	 stakeholders	
‘speak’	from	the	same	platform	–	the	county	drug	treatment	centres.	The	‘professionalisation’	of	
drug	 treatment	 –	 as	 the	 changes	were	 defined	 as	 –	 created	 a	 platform	where	medical	 doctors	
could	 deliver	 methods	 and	 treatment	 models	 that	 supported	 this	 ‘professionalisation’.	 The	
increased	 focus	 on	 health	 and	 health-related	 harms	 with	 the	 spread	 of	 harm	 reduction	
perspectives	in	Danish	drug	policy	also	made	other	medical	professionals,	such	as	nurses,	a	more	
prominent	group	of	stakeholders	in	substitution	treatment.	The	changes	in	1996	led	to	an	increase	
of	drug	users	in	treatment.	The	overall	idea	was	that	it	was	better	to	have	drug	users	in	treatment	
than	not	in	treatment	became	prominent,	and	that	this	would	not	only	result	in	better	health	and	
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lower	overdose	rates	for	the	drug	users,	but	also	reduce	their	criminal	activities	and	nuisance	to	
the	public.		
Despite	 the	 unification	 of	 drug	 treatment	 in	 county-based	 drug	 treatment	 centres,	
substitution	 treatment	 is	 still	 embedded	 in	 two	 policy	 areas:	 health	 policy	 (prescription	 of	
substitution	 medicine)	 and	 social	 policy	 (provision	 of	 the	 psychosocial	 treatment	 elements	 in	
substitution	 treatment)	 and	 consequently	 is	 regulated	 by	 two	 sets	 of	 guidelines,	 as	 discussed	
above.	It	is,	however,	not	only	drug	treatment	that	makes	up	Danish	drug	policy,	but	also		control	
policy	and	harm	reduction	initiatives.	The	focus	of	our	analyses	below	is	limited	to	how	and	what	
role	medical	professionals	have	played	in	drug	policy	developments	during	the	past	ten	to	fifteen	
years	in	Denmark,	including	how	the	increasing	trend	to	medicalisation	has	given	space	to	medical	
professionals	and	their	perspectives	as	well	as	practices	in	substitution	treatment.		
	
UK	
In	the	UK	medical	stakeholders	have	been	involved	in	the	development	of	drugs	treatment	policy	
and	 practice	 since	 the	 latter	 half	 of	 the	 19th	 century	 (Berridge,	 2013).	 By	 1926,	 the	 Rolleston	
report6	defined	addiction	as	a	‘disease’	and	legitimized	heroin	maintenance	prescribing.	GPs	were	
the	key	professional	 stakeholders	within	 this	 framework	and	decisions	about	prescribing	were	a	
matter	 of	 their	 clinical	 judgment.	 This	 phase	 of	 policy	 from	 1926	 to	 the	 early	 1960s	 is	 often	
referred	to	as	the	‘British	system’	of	drugs	control.	However,	rather	than	representing	a	victory	of	
medicine	over	criminal	justice,	this	was	an	alliance	between	the	medical	profession	and	the	state	
and	 also	 between	 the	 Home	 Office	 and	 the	 Ministry	 of	 Health	 (Berridge,	 1984).	 Similar	 to	
Denmark,	there	were	low	numbers	of	‘addicts’	at	this	time,	mainly	middle	class,	middle-aged	and	
of	a	therapeutic	origin	(ie.	those	who	had	become	dependent	as	a	result	of	taking	opiate	drugs	for	
another	 condition)	 (Mold,	 2008,	 p.	 20),	 which	 allowed	 for	 a	 general	 ‘laissez	 faire	 medicalised	
approach’	 towards	 addiction	 to	 emerge	 during	 this	 period.	 By	 the	 1960s,	 the	 growing	 drugs	
subculture	and	the	over-prescribing	by	some	doctors	were	important	factors	prompting	a	shift	in	
policy	(Berridge,	1999).	In	this	period	drugs	treatment	shifted	from	the	general	practitioners	in	the	
community	 towards	 specialist	 addiction	 psychiatrists	 in	 hospital-based	 settings.	 Although	
addiction	was	re-defined	to	include	a	social	dimension,	medical	professionals	-	now	including	both	
psychiatrists	and	GPs	-	were	important	stakeholders	in	the	field	(Berridge,	2013).	In	practice,	policy	
was	determined	locally	by	the	individual	psychiatrists	in	the	new	Drug	Dependence	Units	(DDUs)	
which	effectively	 functioned	as	prescribing	centres	(Mold,	2008).	While	discussions	around	what	
drug,	oral	methadone	or	heroin,	should	be	used	in	treatment	as	well	as	discussions	around	what	
																																								 																				
6	The	Departmental	Committee	on	Morphine	and	Heroin	Addiction	(known	as	the	Rolleston	Committee	and	chaired	by	
Sir	Humphrey	Rolleston)	was	appointed	by	the	Ministry	of	Health	in	1924	to	investigate	morphine	and	heroin	use.	The	
membership	of	the	Committee	was	composed	entirely	of	medical	men	who	viewed	heroin	use	at	the	time	as	a	
medical	problem	which	could	be	controlled	through	treatment	by	the	medical	profession	(see	Mold,	2008,	pp.	18-21).			
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the	goal	of	treatment	should	be,	maintenance	or	abstinence,	the	medical	professionals	were	still	
key	 stakeholders	 in	 defining	 substitution	 treatment	 (Hartnoll	 et	 al,	 1980;	 Stimson	 and	
Oppenheimer,	 1982;	 Strang	 and	 Gossop,	 1994).	 	 By	 1976,	 oral	 methadone	 replaced	 injectable	
drugs	 (including	heroin	and	methadone)	as	 the	main	 form	of	 treatment	 for	patients	new	to	 the	
DDUs	(Mold,	2008)	
By	 the	 late	 1970s	 and	 early	 1980s,	 many	 of	 the	 key	 assumptions	 underpinning	 drug	
treatment	were	challenged.	For	example,	the	use	of	indefinite	maintenance	prescribing	was	being	
questioned	 and	 a	 wider	 social	 approach	 for	 dealing	 with	 drug	 problems	 was	 advocated	 which	
included	addressing	housing,	employment	and	 training	 issues	 (MacGregor	and	Ettorre,	1987).	 In	
1982,	the	Advisory	Council	on	the	Misuse	of	Drugs	(ACMD)	argued	that	drug	problems	extended	
beyond	 the	 clinical	 discourses	 of	 dependence	 and	 required	more	 than	 just	 a	medical	 response	
(ACMD,	1982).	In	1984,	new	guidelines	for	the	management	of	drug	dependence	were	published	
for	 general	 practitioners	 on	 short-term	 prescribing	 and	 less	 complicated	 cases	 of	 methadone	
maintenance	 treatment	 (Farrell	 and	 Raistrick,	 2005).	 	 However,	 just	 as	 these	 new	 ideas	 and	
conceptualisations	 began	 to	 embed	 themselves	 in	 policy	 and	 practice,	 British	 drugs	 policy	 was	
shaped	by	a	heroin	epidemic	associated	with	a	younger	group	of	‘new	heroin	users’	who	tended	to	
be	 concentrated	 in	 areas	 with	 high	 levels	 of	 unemployment	 and	 social	 deprivation	 (Pearson,	
1987).	The	1985	drug	strategy	marked	an	important	shift	 in	emphasis	as	enforcement	and	penal	
measures	were	given	much	more	prominence	to	control	the	growing	drugs	problem	(Home	Office,	
1985).	However,	 by	 the	 late	 1980s,	 the	 advent	of	HIV/AIDS	ensured	 that	 a	 harm	 reduction	 and	
public	 health	perspective	was	 revived	 and	 co-existed	within	 this	 overall	 penal	 and	enforcement	
framework.	 	 	 Harm	 reduction	 initiatives,	 such	 as	 needle	 exchange	 and	 a	 renewed	 emphasis	 on	
methadone	prescribing,	were	introduced.	New	guidelines	were	published	in	1991	which	included	
advice	 for	 injectors	 on	 how	 to	 clean	 injecting	 equipment	 in	 order	 to	 reduce	 the	 risk	 of	 HIV	
transmission	(Farrell	and	Raistrick,	2005).	Psychiatry	remained	in	a	dominant,	directive	position	in	
drugs	treatment,	particularly	in	relation	to	maintenance	prescribing,	but	general	practitioners	re-
emerged	 again	 to	 play	 roles	 in	 caring	 for	 drug	 users	 (Mold,	 2008).	 A	 new	 layer	 of	 community-
based	 drug	 treatment	 services	 funded	 through	 the	 Central	 Funding	 Initiative	 (CFI)	 were	 also	
created	(MacGregor,	1994).	The	policy	community	around	drugs	broadened	during	the	1980s	and	
1990s	 to	 include	new	stakeholders	 such	as	 social	workers,	probation	officers,	 infectious	disease	
specialists,	public	health	professionals,	GPs,	and	a	reshaped	voluntary	sector.	Medicine	continued	
to	play	a	central	 role	as	doctors	 remained	 in	 their	 formal	expert	advisory	positions	and	medical	
civil	 servants	 played	 important	 roles	 influencing	 policy.	 At	 the	 same	 time,	 there	 was	 a	
downgrading	of	medical	advice	in	relation	to	drugs	as	they	became	the	focus	of	a	wider	range	of	
stakeholders	with	the	rise	of	the	non-medical	voluntary	sector	(Berridge,	1997).		In	1996,	despite	
fears	 that	 substitution	 treatment	 would	 be	 limited,	 a	 Task	 Force	 reviewed	 current	 treatment	
approaches	and	supported	the	role	methadone	maintenance	treatment	and	further	investment	in	
treatment	interventions	(Farrell	and	Raistrick,	2005).	By	the	1990s,	there	were	also	new	emphases	
in	British	drugs	policy	on	drug-related	crime,	involvement	of	the	wider	community	and	partnership	
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approaches	following	the	publication	of	the	new	national	drugs	strategy,	Tackling	Drugs	Together	
(HM	Government,	1995).	
From	 1997	 to	 2010,	 Labour	 governments	 had	 a	 profound	 impact	 upon	 developments	 in	
drugs	 treatment,	 particularly	 in	 relation	 to	 methadone	 maintenance	 prescribing.	 Drawing	 on	
evidence	from	the	US	that	treatment	within	the	criminal	justice	system	could	be	effective,	crime	
reduction	had	become	a	key	priority	of	drugs	treatment	policy.	The	discourses	of	‘tough	on	crime’	
and	‘tough	on	the	causes	of	crime’	(i.e.	drugs	use)	allowed	both	criminal	justice	and	health	to	have	
an	input	into	drugs	policy	which	had	universal	political	appeal	(Duke,	2006).	Most	importantly,	 it	
enabled	 support	 for	 more	 resources	 and	 long-term	 investment	 in	 the	 drug	 treatment	
infrastructure.		Over	this	period,	spending	on	treatment	increased	dramatically	from	£142	million	
in	 2001/02	 to	 £406	 million	 in	 2009/10	 (Drugscope,	 2009),	 increasing	 numbers	 of	 drug	 users	
entered	 formal	 treatment,	waiting	 times	 for	 treatment	decreased,	and	the	drugs	workforce	also	
increased	substantially	(National	Treatment	Agency,	2009).		
Under	 the	 rhetoric	 of	 evidence-based	 policy,	 the	 Labour	 government	 also	 invested	
substantial	sums	of	money	in	research	which	expanded	the	knowledge	and	understanding	of	drugs	
treatment.	A	clear	conclusion	which	emerged	from	various	pieces	of	research	was	that	‘treatment	
works’	(Godfrey	et	al,	2004;	Donmall	et	al,	2009).	Methadone	prescribing	became	one	of	the	key	
tools	 to	 reduce	drug-related	crime.	The	primary	 focus	of	policy	was	 to	expand	 treatment	which	
left	 medical	 stakeholders,	 particularly	 addiction	 psychiatrists	 and	 general	 practitioners	 in	 their	
prescribing	 roles,	 in	 control	 of	 drug	 treatment	 policy	 and	 practice.	 In	 1999,	 revised	 clinical	
guidelines	(known	as	the	‘Orange	Book’)	were	published	which	recommended	a	tighter	monitoring	
and	supervision	of	methadone	to	reduce	diversion	of	drugs	and	overdoses	and	three	levels	of	skill	
and	 corresponding	 training	 were	 defined	 –	 the	 ‘generalist’,	 the	 ‘specialist-generalist’	 and	 the	
‘specialist’	 (Farrell	 and	 Raistrick,	 2005).	 A	 shared	 medical	 hegemony	 between	 psychiatry	 and	
public	health	dominated	drugs	policy-drugs	treatment	during	this	period.	Key	roles	were	played	by	
addiction	psychiatrists,	such	as	Prof	Dr	John	Strang	and	Dr	Brian	Kidd,	and	by	general	practitioners,	
such	as	Dr	Chris	Ford	and	Dr	Roy	Robertson.	Their	work	was	underpinned	by	powerful	historical	
institutions	 such	 as	 the	 Royal	 College	 of	 Psychiatrists	 and	 the	 Royal	 College	 of	 General	
Practitioners,	 as	 well	 as	 the	 organisation,	 Substance	 Misuse	 Management	 in	 General	 Practice	
(SMMGP).	 However,	 the	 overriding	 goal	 of	 the	 new	 treatment	 interventions,	 particularly	 in	 the	
criminal	 justice	 system,	 had	 become	 the	 reduction	 of	 drug-related	 crime	 and	 regulating	 the	
behaviour	 of	 problem	 drug	 users	 (see	 Duke,	 2006;	 Seddon	 et	 al,	 2008;	 Parker,	 2004;	 Stevens,	
2010;	 Shiner,	 2012).	 Challenges	 to	 this	 medical	 hegemony	 began	 to	 appear	 as	 methadone	
maintenance	was	questioned	and	a	new	‘recovery’	discourse	emphasizing	abstinence	emerged	in	
British	drugs	policy	and	practice.			
The	next	sections	of	 the	paper	will	explore	 the	ways	 in	which	medical	 stakeholders	have	
navigated	through	the	current	shifts	within	drugs	policy	and	practice	in	Denmark	and	the	UK.	
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From	social	problem	to	medical	issue:	The	Danish	case	
The	 dual	 responsibility	 for	 drug	 treatment	 in	 Denmark,	 where	 the	 Ministry	 of	 Health	 and	 the	
National	Board	of	Health	are	responsible	for	prescription	drugs	and	the	Ministry	of	Social	Affairs	is	
responsible	for	drug	free	treatment	as	well	as	the	psychosocial	aspects	of	substitution	treatment,	
has	resulted	in	strong	platforms	for	different	stakeholders.	Medical	professionals	have	been	able	
to	make	their	voices	heard	through	the	channels	related	to	the	Ministry	of	Health	and	the	National	
Board	 of	 Health	 and	 Medicine,	 while	 other	 stakeholders,	 such	 as	 current	 or	 ex-drug	 users,	
politicians	or	social	workers,	have	leaned	towards	the	Ministry	of	Social	Affairs’	policy	on	the	topic.	
The	relationship	between	the	two	ministries	has	also	been	a	matter	of	balance	and/or	dominance.	
As	outlined	above,	drug	addiction	was	 from	the	early	1970’s	 to	 the	mid-1990’s	understood	as	a	
social	problem	rather	 than	a	health	problem.	Services	were	directed	mainly	 towards	addressing	
social	problems	and	an	understanding	of	addiction	as	rooted	in	social	circumstances	(e.g.	lifestyle,	
poverty,	unemployment,	lack	of	education).	While	it	has	never	been	an	‘either/or’	in	Denmark,	but	
rather	a	situation	where	both	understandings	have	operated	simultaneously,	with	‘drug	addiction	
as	a	social	problem’	being	the	dominant	understanding,	we	see	a	shift	in	this	balance	around	2000.	
Drug	addiction	becomes	more	and	more	a	 ‘health	problem’,	not	only	 in	relation	to	how	to	treat	
the	 problem,	 but	 also	 in	 relation	 to	 drug	 use	 as	 a	 health	 damaging	 lifestyle	 that	 needs	 health	
interventions	 which	 target	 complications	 following	 drug	 use.	 Three	 areas	 of	 change	 provided	
platforms	 for	 medical	 stakeholders	 to	 challenge	 hitherto	 the	 dominating	 social	 problem	
perspective	on	drug	treatment.	
One	key	 issue	regarding	this	shift	can	be	traced	to	the	fact	that	addiction	medicine	
became	more	professionalized	(Frank,	et	al,	2013).	In	the	wake	of	the	re-organisation	of	the	field	
in	 1996	 to	make	 it	more	 unified,	 there	was	 a	 growing	 debate	 about	 the	 lack	 of	 guidelines	 and	
standard	 for	 the	 medical	 part	 of	 substitution	 treatment.	 Such	 tools	 were	 almost	 non-existent,	
meaning	 that	dosages	of	 substitution	medicine,	 control	measures,	 sanctions	etc.	were	managed	
more	or	less	randomly	according	to	local	doctors´	judgments	(Narkotikarådet,	1998).	According	to	
one	of	the	founders	of	Danish	Society	for	Addiction	Medicine	in	1999,	the	entire	Society	revolved	
around	these	issues.	Drawing	on	international	experiences	and	work	especially	in	the	UK	and	the	
US,	where	addiction	medicine	had	a	very	dominant	role,	the	founders	of	the	Society,	who	all	held	
important	positions	 in	 the	 field,	managed	 to	 influence	 the	policy	processes	 leading	 to	 the	2008	
prescription	 guidelines	 (see	 above).	 The	 aims	 of	 these	 guidelines	were	 to	 standardize	 and	 to	 a	
larger	extent	unify	Danish	methadone	prescription	practices	and	at	the	same	time	to	ensure	the	
rights	 of	 the	 users	 in	 medical	 substitution	 treatment.	 The	 voices	 of	 the	 medical	 stakeholders	
coincided	 with	 broader	 societal	 developments	 including	 the	 increasing	 demands	 towards	
evidence-based	 treatment	 practices,	 monitoring	 and	 documentation	 in	 welfare	 and	 health	
services	(Frank	et	al.,	2013;	Bjerge,	2012).	 In	that	sense,	the	agenda	of	the	medical	stakeholders	
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fitted	 nicely	 together	with	 the	 political	 context	 at	 the	 time	which	made	 it	 fairly	 easy	 for	 these	
stakeholders	to	get	their	voices	heard.	
Another	key	 issue	regarding	an	 increased	role	of	medical	stakeholders	 is	 related	to	
an	 increased	 focus	 on	 health	 care	 (Frank	 et	 al,	 2013).	 From	 the	 1990s,	 a	 concern	 amongst	
treatment	professionals,	administrators	and	relatives	of	drug	users,	and	the	general	public	can	be	
traced	to	the	fact	that,	a	growing	number	of	“older”	drug	users	did	not	benefit	from	regular	social	
and	health	services	as	their	physical,	social	and	mental	conditions	worsened	due	to	long	histories	
of	 intravenous	 drug	 use	 and	 associated	 illnesses	 e.g.	 hepatitis,	 HIV/AIDS,	 or	 different	 kinds	 of	
endocarditis.	More	specialized	services	were	required,	but	it	was	not	until	the	beginning	of	2000	
that	medical	 professionals	 increased	 in	 numbers	 in	 treatment	 centres.	 As	 a	 treatment	 provider	
reported:		
At	 the	 beginning	 of	 the	 millennium	 there	 were	 10	 nurses	 employed	 in	 services	
directed	 toward	 drug	 users	 in	 the	municipality	 of	 Copenhagen.	 Today	 [2012]	 there	
are	 approximately	 120	 nurses	 employed	 in	 the	municipality	 (quoted	 in	 Frank	 et	 al.	
2013:	1003).	
This	trend	is	also	seen	in	other	municipalities	in	Denmark.	In	all	large	cities	in	Denmark,	a	variety	of	
health	services	have	now	been	established	such	as	street	nurses,	services	screening	for	hepatitis,	
safe	 injection	 rooms	 etc.,	 which	 have	 pushed	 medical	 and	 health	 professionals	 into	 roles	 as	
agenda	setting	stakeholders	in	the	field	in	the	sense	that	their	voices	were	now	included	as	key	to	
various	 local	 drug	 projects.	 Furthermore,	 this	 increased	 focus	 on	 health-related	 issues	 has	
provided	 space	 for	 the	 development	 of	 heroin-assisted	 treatment	 as	 a	means	 to	 accommodate	
severely	 marginalized	 users	 in	 order	 to	 reduce	 their	 health	 risk	 behaviours	 and	 use	 of	 illegal	
substances,	as	well	as	to	reduce	crime	and	improve	their	social	situations.		
A	 third	 issue	 that	 has	 increased	 the	 position	 of	 medical	 stakeholders	 in	 the	 field	
relates	to	an	increased	focus	on	dual	diagnosis.	According	to	one	stakeholder,	a	report	published	
from	 the	 then	 Narcotics	 Council	 in	 1999	 (Narkotikarådet,	 1999),	 an	 advisory	 body	 to	 the	
government,	kick-started	discussions	of	how	to	manage	mentally	ill	drug	users	better	in	the	drug	
treatment	 system.	 In	 the	 wake	 of	 these	 discussions,	 different	 local	 projects	 focusing	 on	 this	
particular	issue	were	set-up	and	many	of	these	were	inspired	by	research	and	projects	in	the	US,	
UK	and	other	Nordic	countries	 (Frank	et	al.,	2013).	Furthermore,	 in	2008	the	revised	Circular	on	
the	Prescription	of	Addictive	Drugs	 included	guidance	on	how	the	drug	treatment	system	should	
diagnose	mental	illnesses	and	how	dual-diagnosed	users	should	be	dealt	with	(Sundhedsstyrelsen,	
2008).	 This	 development	 was	 not	 only	 supported	 by	 medical	 professionals,	 but	 also	 social	
treatment	providers	and	users	themselves	wished	for	a	broader	understanding	of	explanations	of	
drug	 use,	 according	 to	 stakeholders	 interviewed.	 Again,	 this	 parallels	 with	 broader	 societal	
developments	 towards	 increased	 focus	 on	medical	 explanations	 and	 solutions	 to	 understanding	
and	handling	deviant	behavior	 (e.g.	 the	 increased	 focus	on	ADHD	and	 the	use	of	Ritalin	 among	
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youth	with	challenging	behaviour)	(Jones	2014;	Frank	et	al	2013).	These	developments	provide	yet	
another	 space	 for	 medical	 stakeholders	 to	 challenge	 the	 social	 problem	 approach	 to	
understanding	and	handling	drug	use.							
	 In	sum,	the	increasing	medicalisation	in	Denmark	is	rooted	in	organisational	changes	
in	substitution	treatment;	the	emergence	of	professional	organisations	of	medical	stakeholders;	a	
push	for	documentation;	evidence	and	international	standards;	intensified	focus	on	health-related	
problems;	and	policies	and	local	initiatives	focusing	on	dual-diagnosis.				
	
The	rise	of	‘recovery’	and	the	challenge	to	‘medical	hegemony’	in	the	UK	
From	2005,	methadone	maintenance	was	re-framed	as	problematic	by	a	number	of	stakeholders	
including	 researchers,	 think	 tanks,	 the	 media	 and	 those	 working	 in	 the	 abstinence-based	
residential	 rehabilitation	 sector	 (see	 Duke	 et	 al,	 2013).	 Existing	 research	 evidence	 was	 re-
interpreted	 to	 emphasise	 the	 low	 numbers	 exiting	 from	 drug	 treatment,	 rather	 than	 harm	
reduction	benefits	of	keeping	people	in	treatment	(see	Duke	and	Thom,	2014	for	a	more	detailed	
analyses	on	how	evidence	was	used	by	different	 stakeholders	within	 the	debates).	At	 the	 same	
time,	 revised	 clinical	 guidelines	 were	 published	 in	 2007	 to	 provide	 frameworks	 for	 medical	
practitioners	to	develop	good	practice	and	cost	effectiveness	in	pharmacological	interventions.		In	
the	 lead	 up	 to	 the	 general	 election	 in	 May	 2010,	 the	 Conservatives	 promised	 to	 deliver	 an	
abstinence-based	drug	 strategy.	 The	 right	wing	Centre	 for	 Social	 Justice	 argued	 that	 the	 Labour	
policy	 on	 drugs	with	 its	 harm	 reduction	 ethos	 had	 failed	 and	 referred	 to	 the	 ‘entrenchment	 of	
addiction’	 and	 ‘intergenerational	 cycles	 of	 addiction’	 (Centre	 for	 Social	 Justice,	 2007:	 10).	 The	
report	argued	that	the	voluntary	sector	had	become	‘colonised’	to	promote	harm	reduction	which	
had	stifled	innovation	and	the	development	of	holistic	services.	The	medical	approach,	particularly	
methadone	 maintenance	 prescribing,	 was	 blamed	 for	 perpetuating	 addiction	 and	 dependency.	
The	role	of	 the	medical	profession	 in	dealing	with	addiction	was	subjected	to	challenge	and	the	
emerging	critique	is	captured	in	this	extract	from	an	interview	with	a	researcher	who	had	become	
disillusioned	with	the	ways	in	which	drug	treatment	had	developed:	
“in	 essence	what	we	had	was	 a	massively	 expanding	 industry,	 that	 essentially	was	 hugely	
self-serving	 for	 lots	 of	 the	 people	 that	worked	 in	 it,	 but	 just	 didn’t	 do	much	 good	 for	 the	
clients	who	accessed	it…we	were	living	in	a	psychiatrist’s	conspiracy	that	virtually	all	of	the	
research	pounds,	the	policy	pounds	and	the	intellectual	attention,	all	the	effort	and	focus	was	
on	an	acute	care	system	and	with	absolutely	no	interest	in	what	happened	to	people	that	did	
manage	to	get	through	and	come	out	the	other	end.”		
Despite	the	lack	of	UK	evidence	on	recovery	(see	Best	et	al,	2010)	when	the	policy	document	was	
published,	the	overarching	theme	of	the	2010	drugs	strategy	was	‘recovery’	and	signaled	a	move	
away	 from	 a	 harm	 reduction	 perspective	 and	 the	 reliance	 on	 methadone	 maintenance	 as	 a	
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treatment	 tool.	 Although	 the	 strategy	 specifies	 that	 ‘recovery	 involves	 three	 over-arching	
principles	 –	 well-being,	 citizenship,	 and	 freedom	 from	 dependence’,	 it	 concedes	 that	 recovery	
would	not	be	explicitly	defined:	“It	is	an	individual,	person-centred	journey,	as	opposed	to	an	end	
state,	 and	 one	 that	will	mean	 different	 things	 to	 different	 people”	 (HM	Government,	 2010:18).	
However,	the	focus	would	shift	from	process	driven	targets	(e.g.	accessing	treatment)	to	outcome-
based	 targets	 such	 as	 freedom	 from	drugs	 and	 alcohol	 dependence;	 prevention	of	 drug-related	
death	and	blood	borne	viruses;	 reduction	 in	crime	and	offending;	sustained	employment;	stable	
housing;	 improvements	 in	 physical	 and	 mental	 health;	 improved	 relationships	 with	 family	 and	
friends;	and	capacity	 to	be	an	effective	parent.	The	strategy	would	be	underpinned	by	a	 ‘whole	
systems	 approach’	 and	 would	 draw	 on	 a	 range	 of	 services	 including	 education,	 training,	
employment,	housing,	family	support,	health,	prisons,	probation	and	youth	justice.	The	changes	in	
drugs	 policy	 were	 occurring	 alongside	 shifts	 within	 the	 wider	 political,	 economic	 and	 social	
contexts	with	increasing	emphasis	on	the	neo-liberal	agenda,	massive	cuts	to	the	public	sector	and	
the	global	recession	(Duke,	2013).		In	the	drugs	field,	the	closure	of	the	National	Treatment	Agency	
(NTA),	 the	 government	 agency	 dedicated	 to	 drug	 treatment,	 is	 indicative	 of	 these	 trends.	 The	
community	 would	 be	 expected	 to	 fill	 the	 gaps	 left	 by	 the	 cuts	 and	 dis-investment	 in	 drug	
treatment	 provision.	 These	 changes	 coincided	 with	 the	 growing	 recovery	 movement	 which	
operates	at	the	grassroots	level	where	recovery	communities	and	peer	support	play	fundamental	
roles	 (Duke,	 2013).	 There	 would	 be	 greater	 emphasis	 on	 abstinence,	 self-help	 and	 mutual	 aid	
forms	of	support,	rather	than	relying	on	state	provision	and	the	traditional	medical	professionals,	
such	as	psychiatrists	and	general	practitioners.	At	the	level	of	official	policy	rhetoric,	 it	appeared	
that	the	role	of	medical	stakeholders	in	drug	treatment	would	become	less	prominent	under	the	
new	strategy.	
After	the	publication	of	the	2010	drug	strategy	document,	the	NTA	appointed	Prof	Dr	
John	Strang,	an	addiction	psychiatrist,	 to	chair	an	expert	group	to	review	the	evidence	base	and	
develop	 a	 clinical	 consensus	 around	 the	 use	 of	 OST	 within	 a	 recovery-oriented	 treatment	
framework.	 Based	 on	 this	 review	 of	 evidence,	 they	 concluded	 that	 OST	 “has	 an	 important	 and	
legitimate	 place	within	 recovery-orientated	 systems	 of	 care”	 (NTA,	 2012:5).	 There	would	 be	 no	
time	limits	placed	on	prescriptions	but	equally	rigorous	monitoring	systems	would	be	established	
to	ensure	that	a	balance	was	achieved	between	promoting	overcoming	dependency	and	reduction	
of	 harm.	 Although	 the	 expert	 group	 included	 a	 diverse	 range	 of	 representatives	 from	 various	
perspectives,	 disciplines	 and	 backgrounds,	 some	 stakeholders	 saw	 the	 expert	 group	 as	 the	
continued	 dominance	 of	 psychiatry	 and	 protectionism	 around	 prescribing	 models	 and	 medical	
expertise.	There	was	skepticism	about	how	far	recovery	had	developed	the	way	 it	was	originally	
envisaged:			
“...the	 various	 bodies	 and	 chairs	 just	 make	 sure	 that	 all	 the	 nurses	 and	 doctor	 jobs	 are	
protected	first	and	all	the	things	that	really	the	spirit	of	a	recovery	model	was	supposed	to	
ensure,	 you	 know	 community	 focused	 activity,	 asset	 based	 community	 development,	 peer	
13	
	
empowerment,	a	much	greater	 focus	on	 community	and	 residential	 rehabilitation,	none	of	
those	things	have	happened.”	(interview	with	recovery	advocate)	
Some	 recovery	 advocates	 suggested	 this	 was	 the	 case	 of	 the	 ‘old	 guard	 implementing	 new	
ideas’,	growing	 ‘professionalisation	of	recovery’	and	an	extension	of	medical	dominance.	One	
researcher	commented	on	the	lack	of	engagement	from	some	self-help	organisations:	
”AA,	 NA	 -	 those	 organisations	 have	 not	 really	 been	 very	 vocal	 in	 terms	 of	 the	 recovery	
agenda	and	regrettably	so,	because	I	think	it’s	rather	allowed	professionalization	of	recovery	
and	the	further	extension	of	medical	dominance.”	
	
During	the	early	days	of	the	2010	strategy,	there	was	an	indication	that	the	medical	hegemony	of	
British	 drugs	 policy-drugs	 treatment	was	 beginning	 to	wane	with	 the	 shift	 towards	 abstinence-
based	 treatment	 and	 grassroots	 recovery	 movements.	 At	 the	 time	 of	 the	 interviews	 for	 this	
research	 in	 2012,	 respondents	 referred	 to	 the	 ’decline	 of	 addiction	 psychiatry’	 and	 the	 field	
becoming	less	specialised	as	GPs	and	the	voluntary	sector	played	key	roles	in	the	development	of	
services.	 However,	 the	work	 of	 the	 NTA	 expert	 committee	 chaired	 by	 an	 addiction	 psychiatrist	
reinforced	the	continued	role	of	OST	with	its	robust	evidence	base	demonstrating	effectiveness	in	
the	development	of	a	recovery	oriented	treatment	system.		Thus,	medical	stakeholders	who	have	
largely	 controlled	 and	 directed	 the	 development	 of	 drugs	 treatment	 historically	 appear	 to	
continue	to	play	significant	roles	in	future	policy	and	practice	although	their	positions	have	been	
recently	challenged.	
	
Same	 intervention	 –	 different	 pathways:	 Concluding	 remarks	 on	 the	 role	 of	 medical	
stakeholders	in	Denmark	and	the	UK.	
Despite	 similar	 starting	 points	 in	 the	 1960s/1970s,	 when	 both	 Danish	 and	 British	 OST	 services	
were	based	on	oral	methadone	and	some	form	of	psychosocial	treatment	to	respond	to	increasing	
numbers	of	 young	heroin	users,	 the	development	of	drug	 treatment	and	 the	 roles	 that	medical	
stakeholders	occupy	have	been	shaped	by	country-specific	trajectories	and	contexts.	That	 is,	the	
article	 shows	 how	 different	ways	 of	 defining,	 conceptualizing	 and	 problematizing	 drug	 use	 and	
treatment	have	 led	to	the	development	of	different	kinds	of	spaces	 for	medical	professionals	as	
stakeholders	in	particular	substitution	treatment	policies	and	practices.	The	Danish	case	illustrates	
the	 impact	of	 re-conceptualizing	 the	drugs	problem	from	social	 terms	 to	medical	 terms	and	 the	
resultant	 implications	 for	 stakeholder	groups,	particularly	medical	professionals.	 In	 contrast,	 the	
British	 case	 highlights	 the	 dominance	 of	 medical	 conceptualisations	 of	 the	 drugs	 problem	
historically	and	 the	various	attempts	at	 re-defining	 it	 through	a	wider	social	problematization	 in	
the	 early	 1980s,	 as	 well	 as	 the	 inherent	 tensions	 with	 the	 criminal	 justice	 system	 which	 have	
persisted	over	 time.	Reflecting	 the	strong	social	welfare	 tradition	 in	Denmark,	defining	 the	drug	
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problem	in	social	terms	is	much	more	prominent	compared	to	the	UK	where	the	tensions	between	
medical	profession	and	criminal	 justice	have	dominated	the	development	of	policy	and	practice.	
British	drugs	policy	has	generally	been	molded	through	an	accommodation	between	medical	and	
criminal	justice	concerns	(Berridge,	1978;	Stimson	and	Oppenheimer,	1982;	Pearson,	1991).	These	
definitions	 of	 the	 drugs	 problem	 are	 important	 in	 determining	 which	 stakeholder	 groups	 and	
government	 departments	 have	 responsibility,	 power	 and	 influence	 in	 developing	 policy	 and	
practice.	However,	the	ways	in	which	addiction	historically	has	been	institutionalized	in	different	
sectors	of	the	welfare	state,	(for	example	primarily	 in	the	health	or	the	social	sector),	also	 loops	
back	 on	 how	 addiction	 is	 conceptualized	 (cf.	 Hacking,	 1999).	 Furthermore,	 it	 is	 clear	 from	 the	
analyses	above	 that	different	 conceptualisations	can	operate	 simultaneously,	but	one	 form	may	
be	more	dominant	at	particular	junctures	(Kingdon,	1995).	
The	British	case	demonstrates	how	the	number	of	 stakeholders	 in	drugs	policy	has	
increased	 and	 changed	 over	 time.	 Since	 the	 1990s,	 policy	 initiatives	 have	 placed	 emphasis	 on	
‘partnership’	 and	 ‘multi-agency’	 working	 which	 has	 increased	 the	 number	 and	 diversity	 of	
stakeholders	involved.	Over	time,	this	has	presented	challenges	to	the	medical	models	dominating	
drug	 treatment.	This	can	be	seen	especially	 in	 the	 recent	phase	of	policy	development	with	 the	
emphasis	on	 ‘recovery’	and	the	debates	regarding	what	 this	shift	means	 for	policy	and	practice.	
Similarly,	emphasis	on	abstinence,	rather	than	maintenance,	has	also	challenged	the	reliance	on	
some	forms	of	medical	expertise,	particularly	in	relation	to	prescribing.	Recent	research	by	Neale	
et	 al	 (2014,	 2015)	 with	 a	 variety	 of	 stakeholders	 including	 addiction	 psychiatrists,	 staff	 from	
residential	rehabilitation	and	detoxification	units,	and	service	users,	has	highlighted	that	there	 is	
growing	 consensus	 that	 ‘recovery’	 extends	 beyond	 the	 simple	 measure	 of	 abstinence	 and	
encompasses	 a	wide	 range	of	 social,	 psychological,	 physical,	 financial	 and	 spiritual	 changes,	 but	
there	is	continued	disagreement	and	debate	on	particular	measures	of	progress.	In	a	similar	vein,	
the	Danish	case	demonstrates	that	the	variety	of	stakeholders	in	drugs	policy	has	increased	over	
time,	 but	 contrary	 to	 the	 UK,	 the	 balance	 between	 different	 stakeholders	 has	 changed	 so	 that	
medical	professionals,	especially	doctors	and	nurses,	are	now	much	more	prominent	in	the	field.	
In	 this	 process	 the	 dominating	 social	model	 of	 drug	 treatment	 has	 been	 challenged	 by	medical	
models.	Despite	the	increased	focus	on	health	related	harm	and	maintenance,	which	has	been	a	
consequence	 of	 this	 shift	 towards	 OST,	 other	 kinds	 of	 treatment	 interventions	 have	 not	 been	
neglected	 in	 Danish	 treatment	 policies	 and	 services,	 including	 residential	 treatment	 and	 harm	
reduction	services	(Pedersen,	Hesse	&	Bloomfield,	2011;	Houborg,	2010)	.			
Shifts	in	the	power	and	position	of	different	stakeholder	groups		can	occur	because	
of	changes	in	the	extent	and	nature	of	drug	use,	perceptions	of	crisis/problem	(i.e.	HIV/AIDS	or	an	
aging	drug	user	population),	political	influence,	wider	trends	in	social,	health	and	criminal	justice	
policy	or	external	influences	of	research	from	other	countries	such	as	the	increasing	demands	for	
evidence	 (cf.	 Kingdon,	 1995).	 Furthermore,	 shifts	 can	 also	 be	 promoted	 by	 the	 work	 of	
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entrepreneurial	 stakeholders	 or	 stakeholder	 groups	 who	 take	 advantage	 of	 changing	 political	
contexts	to	create	a	more	solid	platform	to	get	their	perspectives	heard.		
In	conclusion,	the	rise	of	the	medical	voice	in	the	Danish	substitution	treatment	field	
has	 challenged	 the	 dominant	 idea	 of	 drug	 use	 as	 a	 social	 problem.	 The	 medical	 model	 was	
promoted	by	 a	 group	of	 entrepreneurial	medical	 stakeholders	 and	 facilitated	by	 changes	 in	 the	
organisation	of	drug	treatment,	 the	broader	societal	 focus	on	health,	medication	and	the	use	of	
evidence,	and	demographic	changes	 in	the	drug	user	population.	The	strong	medical	dominance	
within	British	drugs	treatment	has	recently	been	challenged	by	a	“recovery”	movement	 led	by	a	
number	 of	 advocacy	 organisations;	 recovery	 advocates	 from	 the	 United	 States,	 the	 residential	
rehabilitation	sector,	some	researchers	and	media	stakeholders.	 	However,	medical	stakeholders	
regained	 their	 authority	 through	 their	positions	as	expert	 advisors	 and	by	 their	use	of	evidence	
within	the	wider	debates	about	the	future	of	opioid	substitution	treatment.		
It	is	important	to	state	that	the	shifting	roles	of	medical	professionals	and	challenges	
to	the	dominant	conceptualisations	in	drug	policies	and	practices	are	not	to	be	understood	as	an	
“either-	or”	dichotomy	in	either	of	the	two	countries.	In	Denmark,	the	social	problem	approach	is	
still	 recognized	as	key	 in	drug	treatment	practices,	but	 it	has	 lost	some	dominance	compared	to	
fifteen	 years	 ago.	 The	 increased	 roles	 of	medical	 professionals	 have	 been	 encouraged	 by	 social	
workers,	 as	 well	 as	 by	 the	 wider	 society,	 and	 more	 collaboration	 has	 resulted	 between	 the	
different	 areas	 of	 expertise	 (e.g	 harm-reduction	 focused	 services,	 such	 as	 heroin-assisted	
treatment,	have	been	directed	towards	 the	most	marginalized	users).	 In	contrast	 to	 the	UK,	 the	
recovery	movement	has	not	had	a	 strong	voice	 in	 the	Danish	drug	 treatment	 system.	However,	
the	perspective	has	been	highly	influential	in	the	psychiatric	field	in	Denmark,	so	this	may	have	a	
“spill	over”	effect	on	drug	treatment.		In	the	UK,	medical	professionals	continue	to	play	important	
roles	in	drug	treatment	and	policies.	Despite	the	fact	that	the	role	of	substitution	treatment	within	
a	recovery-oriented	approach	has	been	supported	by	a	review	of	evidence,	there	continues	to	be	
skepticism	both	politically	and	 in	some	sectors	of	 the	drug	 field	 towards	 this	approach.	 In	other	
words,	there	does	not	seem	to	be	a	reconciliation	or	merger	of	the	two	approaches	as	yet.	In	both	
countries,	the	struggle	over	who	‘owns’	the	problem	is	ongoing.	
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